Nvidia and Eli Lilly announced a multi‑year co‑innovation effort to embed accelerated computing and AI into drug discovery, committing up to $1 billion over five years to build an "AI lab" for biopharma research. Executives framed the pact at JPM as a scale play to bring high‑performance computing, model development and data co‑design into Lilly’s R&D. Nvidia said the partnerships extend beyond Lilly, with alliances across the drug‑discovery ecosystem including Thermo Fisher and others to deploy AI‑ready lab infrastructure and cloud‑to‑edge tools. Company leaders emphasized compute scale, applied model building, and integrated datasets as the mechanism to compress discovery timelines. The announcements formalize industry moves to combine chipmakers’ compute and model capabilities with pharma’s biological expertise, signaling larger capital and operational bets on AI as a core R&D platform.